

Shreemanta K Parida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8200484/publications.pdf>

Version: 2024-02-01

42
papers

3,566
citations

172457

29
h-index

276875

41
g-index

44
all docs

44
docs citations

44
times ranked

4991
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2021, 39, 3028-3036.	3.8	5
2	Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. <i>Frontiers in Immunology</i> , 2019, 10, 527.	4.8	40
3	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1198-1208.	5.6	217
4	Metabolite changes in blood predict the onset of tuberculosis. <i>Nature Communications</i> , 2018, 9, 5208.	12.8	129
5	<i>Mycobacterium tuberculosis</i> proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model. <i>International Journal of Infectious Diseases</i> , 2017, 56, 274-282.	3.3	8
6	Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties. <i>Biologics: Targets and Therapy</i> , 2017, Volume 11, 55-63.	3.2	14
7	A blood RNA signature for tuberculosis disease risk: a prospective cohort study. <i>Lancet, The</i> , 2016, 387, 2312-2322.	13.7	678
8	B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis. <i>Clinical Infectious Diseases</i> , 2015, 61, S225-S234.	5.8	60
9	Towards host-directed therapies for tuberculosis. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 511-512.	46.4	110
10	Surgical Treatment of Complications of Pulmonary Tuberculosis, including Drug-Resistant Tuberculosis. <i>International Journal of Infectious Diseases</i> , 2015, 32, 61-67.	3.3	34
11	Cellular therapy in Tuberculosis. <i>International Journal of Infectious Diseases</i> , 2015, 32, 32-38.	3.3	26
12	T-Cell Therapy: Options for Infectious Diseases: Table 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, S217-S224.	5.8	42
13	Analysis of Host Responses to <i>Mycobacterium tuberculosis</i> Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa. <i>PLoS ONE</i> , 2013, 8, e74080.	2.5	48
14	Biomarkers of Inflammation, Immunosuppression and Stress Are Revealed by Metabolomic Profiling of Tuberculosis Patients. <i>PLoS ONE</i> , 2012, 7, e40221.	2.5	195
15	The Immunological Footprint of <i>Mycobacterium tuberculosis</i> T-cell Epitope Recognition. <i>Journal of Infectious Diseases</i> , 2012, 205, S301-S315.	4.0	24
16	True facets of TB diagnosis in 2012: Hypes and realities. <i>European Journal of Microbiology and Immunology</i> , 2012, 2, 275-281.	2.8	4
17	Potential of novel <i>Mycobacterium tuberculosis</i> infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. <i>BMC Infectious Diseases</i> , 2012, 12, 10.	2.9	63
18	Potential of Host Markers Produced by Infection Phase-Dependent Antigen-Stimulated Cells for the Diagnosis of Tuberculosis in a Highly Endemic Area. <i>PLoS ONE</i> , 2012, 7, e38501.	2.5	50

#	ARTICLE	IF	CITATIONS
19	Infectious diseases biobanking as a catalyst towards personalized medicine: Mycobacterium tuberculosis paradigm. <i>Tuberculosis</i> , 2011, 91, 524-532.	1.9	14
20	Dendritic Cells Activate and Mature after Infection with Mycobacterium tuberculosis. <i>BMC Research Notes</i> , 2011, 4, 247.	1.4	30
21	A Decade of Interferon- γ Release Assays: Quest for the Holy Grail to Diagnose Latent Infection with Mycobacterium tuberculosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1732-1732.	5.6	1
22	Biomarker discovery in heterogeneous tissue samples -taking the in-silico deconfounding approach. <i>BMC Bioinformatics</i> , 2010, 11, 27.	2.6	95
23	The quest for biomarkers in tuberculosis. <i>Drug Discovery Today</i> , 2010, 15, 148-157.	6.4	105
24	Novel tuberculosis vaccines on the horizon. <i>Current Opinion in Immunology</i> , 2010, 22, 374-384.	5.5	61
25	Biomarkers for tuberculosis disease activity, cure, and relapse. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 68-69.	9.1	64
26	Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of <i>Mycobacterium tuberculosis</i> in Three High-Burden Populations in Africa. <i>Vaccine Journal</i> , 2009, 16, 1203-1212.	3.1	148
27	Biomarkers for tuberculosis disease activity, cure, and relapse. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 162-172.	9.1	164
28	Tuberculosis in Africa: Learning from Pathogenesis for Biomarker Identification. <i>Cell Host and Microbe</i> , 2008, 4, 219-228.	11.0	85
29	An Evaluation of Commercial Fluorescent Bead-Based Luminex Cytokine Assays. <i>PLoS ONE</i> , 2008, 3, e2535.	2.5	137
30	Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations. <i>PLoS Medicine</i> , 2008, 5, e145.	8.4	82
31	Tumor necrosis factor is critical to control tuberculosis infection. <i>Microbes and Infection</i> , 2007, 9, 623-628.	1.9	83
32	Changing funding patterns in tuberculosis. <i>Nature Medicine</i> , 2007, 13, 299-303.	30.7	50
33	Novel Bacterial Delivery System with Attenuated Salmonella typhimurium Carrying Plasmid Encoding Mtb Antigen 85A for Mucosal Immunization: Establishment of Proof of Principle in TB Mouse Model. <i>Annals of the New York Academy of Sciences</i> , 2005, 1056, 366-378.	3.8	19
34	Innate immunity to mycobacterial infection in mice: Critical role for toll-like receptors. <i>Tuberculosis</i> , 2005, 85, 395-405.	1.9	56
35	Reduced Local Growth and Spread but Preserved Pathogenicity of a Δ purC Mycobacterium tuberculosis Auxotrophic Mutant in Gamma Interferon Receptor-Deficient Mice after Aerosol Infection. <i>Infection and Immunity</i> , 2005, 73, 666-670.	2.2	9
36	Toll-like receptor pathways in the immune responses to mycobacteria. <i>Microbes and Infection</i> , 2004, 6, 946-959.	1.9	234

#	ARTICLE	IF	CITATIONS
37	Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens. <i>Immunology Letters</i> , 2003, 86, 299-307.	2.5	66
38	Internalin B is essential for adhesion and mediates the invasion of <i>Listeria monocytogenes</i> into human endothelial cells. <i>Molecular Microbiology</i> , 2002, 28, 81-93.	2.5	155
39	Correlation of tumor necrosis factor levels in the serum and cerebrospinal fluid with clinical outcome in Japanese encephalitis patients. <i>Journal of Medical Virology</i> , 1997, 51, 132-136.	5.0	105
40	Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. <i>Clinical Immunology and Immunopathology</i> , 1992, 63, 23-27.	2.0	38
41	Landscape of Manufacturing Process of ATMP Cell Therapy Products for Unmet Clinical Needs. , 0, , .		6
42	Toll-Like Receptors and Control of Mycobacterial Infection in Mice. <i>Novartis Foundation Symposium</i> , 0, , 127-141.	1.1	8